The same active ingredient does not make two approved products interchangeable.
Bottom line: Ozempic and Wegovy contain semaglutide but have different labeled indications, presentations and instructions. Wegovy HD 7.2 mg is a distinct higher-dose presentation approved in March 2026. [1,2]
| Ozempic | Wegovy | |
|---|---|---|
| Active ingredient | Semaglutide in an Ozempic presentation. | Semaglutide in a Wegovy or Wegovy HD presentation. |
| Use | Follow the current Ozempic indication and label. | Follow the current Wegovy indication and label; Wegovy HD includes a 7.2 mg once-weekly dose for eligible adults. [1,2] |
| Interchangeability | Do not convert doses or devices without the prescriber and label. | Do not infer that another semaglutide product has the same concentration, device, storage or instructions. [2,3] |
summary: Ozempic and Wegovy contain semaglutide but have different labeled indications, presentations and instructions. Wegovy HD 7.2 mg is a distinct higher-dose presentation approved in March 2026. [1,2]
trials: []
No. It compares evidence and status. Use the exact approved label and prescriber plan, or a registered clinical-trial protocol if you are enrolled.
Educational evidence summary. Approved products, patient-specific compounded preparations, clinical-trial products, and research-market products are not interchangeable categories.
